Focus on HDL: a new treatment paradigm for athero-thrombotic vascular disease

Bibliography

• ASSMANN G, CULLEN P, JOSSA F, LEWIS B, MANCINI M: Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease. Arterioscler. Thromb. Vasc. Biol. (1999) 19:1819–1824.
   PubMed Web of Science ®Google Scholar
• LAROSA JC, HE J, VUPPUTURI S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA (1999) 282:2340–2346.
   PubMed Web of Science ®Google Scholar
• MILLER GJ, MILLER NE: Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet (1975) 1:16–19.
   PubMed Web of Science ®Google Scholar
• MILLER GJ, MILLER NE, ASHCROFT MT: Inverse relation-ship in Jamaica between plasma high-density lipopro-tein cholesterol concentration and coronary-disease risk as predicted by multiple risk-factor status. Clin. Sci. Mot. Med. (1976) 51:475–482.
   PubMedGoogle Scholar
• MILLER NE, THELLE DS, FORDE OH, MJOS OD: The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet (1977) 1:965–968.
   Google Scholar
• GORDON T, CASTELLI WP, HJORTLAND MC, KANNEL WB, DAWBER TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J Med. (1977) 62:707–714.
   PubMed Web of Science ®Google Scholar
• HAMSTEN A, WALLDIUS G, SZAMOSI A, DAHLEN G, DE FAIRE U: Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction. Circulation (1986) 73:1097–1110.
   PubMed Web of Science ®Google Scholar
• MILLER NE: High-density lipoprotein: a major risk factor for coronary atherosclerosis. Baillieres Clin. Endocrinol. Metab. (1987) 1:603–622.
   PubMed Web of Science ®Google Scholar
• GORDON DJ: Role of circulating high-density lipopro-tein and triglycerides in coronary artery disease: risk and prevention. Endocrinol. Metab. Clin. North Am. (1990) 19:299–309.
   PubMed Web of Science ®Google Scholar
• GORDON DJ, PROBSTFIELD JL, GARRISON RJ et al.: High-density lipoprotein cholesterol and cardiovas-cular disease. Four prospective American studies. Circulation (1989) 79:8–15.
   PubMed Web of Science ®Google Scholar
• HARPER CR, JACOBSON TA: New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch. Intern. Med. (1999) 159:1049–1057.
   PubMed Web of Science ®Google Scholar
• BROWN WV: Clinical trials including an update on the Helsinki Heart Study. Am] Cardiol (1990) 66:11A–15A.
   Google Scholar
• HEINONEN OP, HUTTUNEN JK, MANNINEN V et al.: The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up. j. Intern. Med. (1994) 235:41–49.
   PubMed Web of Science ®Google Scholar
• HUTTUNEN JK, HEINONEN OP, MANNINEN V et al.: The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J. Intern. Med. (1994) 2 3 5:31–39.
   Google Scholar
• RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density lipopro-tein Cholesterol Intervention Trial Study Group. N Engl. J. Med. (1999) 3 41:410–418.
   Google Scholar
• ERICSSON CG, NILSSON J, GRIP L, SVANE B, HAMSTEN A: Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am. J. Cardiol (1997) 80:1125–1129.
   PubMed Web of Science ®Google Scholar
• DE FAIRE U, ERICSSON CG, GRIP L, NILSSON J, SVANE B,HAMSTEN A: Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials. Cardiovasc. Drugs Ther. (1997) 11 (Suppl. 0:257–263.
   Google Scholar
• BROWN G, ALBERS JJ, FISHER LD et al: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipo-protein B. N Engl. J. Med. (1990) 323:1289–1298.
   PubMed Web of Science ®Google Scholar
• COCKERILL GW, REED S: High-density lipoprotein: multipotent effects on cells of the vasculature. Int. Rev. Cytol. (1999) 188:257–297.
   PubMed Web of Science ®Google Scholar
• PLUMP AS, SCOTT CJ, BRESLOW JL: Human apolipopro-tein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA (1994) 91:9607–9611.
   PubMed Web of Science ®Google Scholar
• RUBIN EM, KRAUSS RM, SPANGLER EA, VERSTUYFT JG,CLIFT SM: Inhibition of early atherogenesis in transgenic mice by human apolipoprotein Al. Nature (1991) 353:265–267.
   PubMed Web of Science ®Google Scholar
• TANGIRALA RK, TSUKAMOTO K, CHUN SH, USHER D, PURE E, RADER DJ: Regression of atherosclerosis induced by liver-directed gene transfer of apolipopro-tein A-I in mice. Circulation (1999) 100:1816–1822.
   PubMed Web of Science ®Google Scholar
• BENOIT P, EMMANUEL F, CAILLAUD JM et al.: Somaticgene transfer of human ApoA-I inhibits atheroscle-rosis progression in mouse models. Circulation (1999) 99:105–110.
   PubMed Web of Science ®Google Scholar
• LINTON MF, FAZIO S: Macrophages, lipoproteinmetabolism and atherosclerosis: insights from murine bone marrow transplantation studies. CUIT. Opin. Lipidol (1999) 10:97–105.
   PubMed Web of Science ®Google Scholar
• BADIMON JJ, BADIMON L, GALVEZ A, DISCHE R, FUSTER V: High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab. Invest. (1989) 60:455–461.
   PubMed Web of Science ®Google Scholar
• BADIMON JJ, BADIMON L, FUSTER V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. (1990) 85:1234–1241.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI A, SAKUMA S, MORIKAWA W et al.: Intrave-nous injection of rabbit apolipoprotein A-Iinhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1882–1888.
   PubMed Web of Science ®Google Scholar
• AMELI S, HULTGARDH-NILSSON A, CERCEK B et al.:Recombinant apolipoprotein A-Imilano reduces intimal thickening after balloon injury in hypercho-lesterolemic rabbits. Circulation (1994) 90:1935–1941.
   PubMed Web of Science ®Google Scholar
• SOMA MR, DONETTI E, PAROLINI C, SIRTORI CR,FUMAGALLI R, FRANCESCHINI G: Recombinant apolipo-protein A-I Milano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ. Res. (1995) 76:405–411.
   PubMed Web of Science ®Google Scholar
• DIMAYUGA P, ZHU J, OGUCHI S et al.: ReconstitutedHDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem. Biophys. Res. Commun. (1999) 264:465–468.
   PubMed Web of Science ®Google Scholar
• WARDEN CH, HEDRICK CC, QIAO JH, CASTELLANI LW, LUSIS AJ: Atherosclerosis in transgenic mice overex-pressing apolipoprotein A-II [published erratum appears in Science 1993 Oct 8;262(5131):164]. Science (1993) 261:469–472.
   PubMedGoogle Scholar
• SCHULTZ JR, GONG EL, MCCALL MR, NICHOLS AV, CLIFT SM, RUBIN EM: Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice. J. Biol. Chem. (1992) 267:21630–21636.
   PubMed Web of Science ®Google Scholar
• SCHULTZ JR, VERSTUYFT JG, GONG EL, NICHOLS AV, RUBIN EM: Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature (1993) 365:762–764.
   PubMed Web of Science ®Google Scholar
• TALL AR: An overview of reverse cholesterol transport. Eur. Heart J. (1998) 1 9 (Suppl. A):A31–A35.
   Google Scholar
• FRUCHART JC, DE GETEIRE C, DELFLY B, CASTRO GR: Apolipoprotein A-I-containing particles and reverse cholesterol transport: evidence for connection between cholesterol efflux and atherosclerosis risk. Atherosclerosis (1994) 110 (Suppl.) :S35–S39.
   Google Scholar
• RODRIGUEZA WV, WILLIAMS KJ, ROTHBLAT GH, PHILLIPS MC: Remodeling and shuttling. Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol. Arterioscler. Thromb. Vasc. Biol. (1997) 17:383–393.
   PubMed Web of Science ®Google Scholar
• BODZIOCH M, ORSO E, KLUCKEN J et al.: The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nature Genet. (1999) 22:347–351.
   PubMed Web of Science ®Google Scholar
• LAWN RM, WADE DP, GARVIN MR et al.: The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J. Clin. Invest. (1999) 1 04 :R25–R31.
   Google Scholar
• RUST S, ROSIER M, FUNKE H et al.: Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genet. (1999) 22:352–355.
   PubMed Web of Science ®Google Scholar
• ACTON S, RIGOTTI A, LANDSCHULZ KT, XU S, HOBBS HH, KRIEGER M: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science (1996) 271:518–520.
   PubMed Web of Science ®Google Scholar
• GU X, TRIGATTI B, XU S, ACTON S, BABITT J, KRIEGER M: The efficient cellular uptake of high density lipopro-tein lipids via scavenger receptor class B Type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain [published erratum appears in J. Biol. Chem. 1998 Dec 25;273(52):35388]. J. Biol. Chem. (1998) 273:26338–26348.
   Google Scholar
• VARBAN ML, RINNINGER F, WANG N et al.: Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein choles-terol. Proc. Nati Acad. Sci. USA (1998) 95:4619–4624.
   PubMed Web of Science ®Google Scholar
• JIN FY, KAMANNA VS, KASHYAP ML: Niacin decreasesremoval of high-density lipoprotein apolipoprotein © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(9) A-I but not cholesterol ester by Hep G2 cells. Implica-tion for reverse cholesterol transport. Arterioscler. Thromb. Vasc. Bid (1997) 17:2020–2028.
   Google Scholar
• KASHYAP ML: Basic considerations in the reversal ofatherosclerosis: significance of high-density lipopro-tein in stimulating reverse cholesterol transport. Am../ Cardiol (1989) 63:56H–59H.
   Google Scholar
• COCKERILL GW, RYE KA, GAMBLE JR, VADAS MA, BARTER PJ: High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1987–1994.
   PubMed Web of Science ®Google Scholar
• COCKERILL GW, SAKLATVALA J, RIDLEY SH et al.:High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler. Thromb. Vasc. Biol. (1999) 19:910–917.
   PubMed Web of Science ®Google Scholar
• GRIFFIN JH, KOJIMA K, BANKA CL, CURTISS LK,FERNANDEZ JA: High-density lipoprotein enhance-ment of anticoagulant activities of plasma protein S and activated protein C. J. Clin. Invest. (1999) 103:219–227.
   PubMed Web of Science ®Google Scholar
• SAKU K, AHMAD M, GLAS-GREENWALT P, KASHYAP ML:Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb. Res. (1985) 39:1–8.
   PubMed Web of Science ®Google Scholar
• LI D, WENG S, YANG B et al: Inhibition of arterialthrombus formation by ApoA1 Milano. Arterioscler. Thromb. Vasc. Bid (1999) 19:378–383.
   PubMed Web of Science ®Google Scholar
• BERLINER JA, NAVAB M, FOGELMAN AM et al: Athero-sclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation (1995) 91:2488–2496.
   PubMed Web of Science ®Google Scholar
• SHIH DM, GU L, XIA YR et al.: Mice lacking serumparaoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature (1998) 394:284–287.
   PubMed Web of Science ®Google Scholar
• WATSON AD, BERLINER JA, HAMA SY et al.: Protectiveeffect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin. Invest. (1995) 96:2882–2891.
   Google Scholar
• AVIRAM M, ROSENBLAT M, BISGAIER CL, NEWTON RS,PRIMO-PARMO SL, LA DU BN: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. j Clin. Invest. (1998) 101:1581–1590.
   PubMed Web of Science ®Google Scholar
• AVIRAM M, BILLECKE S, SORENSON R et al: Paraoxonaseactive site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its aryles-terase/paraoxonase activities: selective action of human paraoxonase allozymes Q and It. Arterioscler. Thromb. Vasc. Bid (1998) 18:1617–1624.
   PubMed Web of Science ®Google Scholar
• AVIRAM M: Does paraoxonase play a role in suscepti-bility to cardiovascular disease? Mot. Med. Today (1999) 5:381–386.
   Google Scholar
• MACKNESS MI, MACKNESS B, DURRINGTON PN et al.: Paraoxonase and coronary heart disease. CUIT. Opin. Lipidol (1998) 9:319–324.
   PubMed Web of Science ®Google Scholar
• MACKNESS M, BOUILLER A, HENNUYER N et al.: Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem. Biophys. Res. Commun. (2000) 269:232–236.
   PubMed Web of Science ®Google Scholar
• SUBBANAGOUNDER G, LEITINGER N, SHIH PT, FAULL KF, BERLINER JA: Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis: in vitro and in vivo inhibition by WEB 2086. Circ. Res. (1999) 85 (4):311–318.
   PubMed Web of Science ®Google Scholar
• SHAH PK, NILSSON J, KAUL S et al.: Effects of recombi-nant apolipoprotein A-I(Milano) on aortic atheroscle-rosis in apolipoprotein E-deficient mice. Circulation (1998) 97:780–785.
   PubMed Web of Science ®Google Scholar
• NANJEE MN, CROUSE JR, KING JM et al.: Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler. Thromb. Vasc. Biol. (1996) 16:1203–1214.
   PubMed Web of Science ®Google Scholar
• NANJEE MN, DORAN JE, LERCH PG, MILLER NE: Acute effects of intravenous infusion of ApoA1/phosphati-dylcholine discs on plasma lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. (1999) 19:979–989.
   PubMed Web of Science ®Google Scholar
• ERIKSSON M, CARLSON LA, MIETTINEN TA, ANGELIN B: Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation (1999) 100:594–598.
   Google Scholar
• MISHRA VK, PALGUNACHARI MN, DATTA G eta].: Studies of synthetic peptides of human apolipoprotein A-I containing tandem amphipathic alpha-helixes. Biochemistry (1998) 37:10313–10324.
   Google Scholar
• RODRIGUEZA WV, MAZANY KD, ESSENBURG AD et al.: Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools. Implications for the treatment of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (1997) 17:2132–2139.
   PubMed Web of Science ®Google Scholar
• WILLIAMS KJ, SCALIA R, MAZANY KD, RODRIGUEZA WV, LEFER AM: Rapid restoration of normal endothelial functions in genetically hyperlipidemic mice by a synthetic mediator of reverse lipid transport. Arterio-scler. Thromb. Vasc. Biol. (2000) 20:1033–1039.
   PubMed Web of Science ®Google Scholar